Literature DB >> 2463650

Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol.

A A Megens1, F H Awouters, C J Niemegeers.   

Abstract

Risperidone, a new antipsychotic agent, was studied for its effects on spontaneous motor activity in rats in comparison with haloperidol. Motor activity was recorded via the optical scanning technique (horizontal and vertical activity) and via a recently developed technique based on the piezo-electric principle which, in contrast to optical scanning, is very sensitive to small, stationary movements (piezo activity). Risperidone and haloperidol at low doses depressed both vertical activity (ED50s: 0.062 and 0.038 mg/kg, respectively) and horizontal activity (0.18 and 0.060 mg/kg, respectively). With increase of dose, motor activity decline was significantly faster with haloperidol than with risperidone. Moreover, haloperidol also rapidly depressed piezo activity (ED50: 0.085 mg/kg) whereas risperidone depressed this component of motor behaviour at much higher doses only (ED50: 2.80 mg/kg). Visual inspection did not reveal abnormal behavioural movements following the test compounds. Risperidone, therefore, preserves normal small movements over a much larger dose interval than haloperidol; this effect may be related to its relatively low cataleptogenic activity and potentially also to a reduced EPS liability. The present results further confirm that the piezo technique may complement the optical scanning method, and thereby enhance the information on the extent that test compounds modify behaviour.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2463650     DOI: 10.1007/bf00172961

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  1 in total

1.  Behavioral activity of rats measured by a new method based on the piezo-electric principle.

Authors:  A A Megens; J Voeten; J Rombouts; T F Meert; C J Niemegeers
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

  1 in total
  6 in total

Review 1.  A risk-benefit assessment of risperidone in schizophrenia.

Authors:  V A Curtis; R W Kerwin
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

2.  Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.

Authors:  H J Möller; J Bäuml; F Ferrero; J Fuger; C Geretsegger; S Kasper; W Kissling; H Schubert
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

3.  Risperidone in Indian patients with schizophrenia.

Authors:  A K Agarwal; V S Bashyam; S M Channabasavanna; H S Dhavale; M A Khan; S Khanna; P V Pradhan; M Katiyar; R Rajkumar; F R Niazi; R K Jalali; R Gowrishankar; S K Mishra; O P Sood
Journal:  Indian J Psychiatry       Date:  1998-07       Impact factor: 1.759

Review 4.  Survey on the pharmacodynamics of the new antipsychotic risperidone.

Authors:  A A Megens; F H Awouters; A Schotte; T F Meert; C Dugovic; C J Niemegeers; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

5.  Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

Authors:  J E Leysen; P M Janssen; A Schotte; W H Luyten; A A Megens
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients.

Authors:  F Mesotten; E Suy; M Pietquin; P Burton; S Heylen; Y Gelders
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.